NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
Open Posted
- Opportunity number
- PAR-24-269
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Categories
-
- Health
- Education
- Eligible applicants
-
- Higher Education Inst. (Public)
- For Profit Organizations
- Small Businesses
- Public or Indian Housing Auth.
- Tribal Governments (Federally Recognized)
- County Governments
- Non-501(c)(3) Nonprofits
- City/Township Governments
- Higher Education Inst. (Private)
- Tribal Organizations (Not Federally Recognized)
- 501(c)(3) Nonprofits
- State Governments
- Special District Governments
- Independent School Districts
- Other
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health is soliciting applications for the NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed) to identify genetic, genomic, and molecular epigenetic variants underlying addictive behaviors, substance use disorder vulnerability, and comorbidities with genetic correlations to addiction phenotypes, with applications due February 11, 2027.
Eligible applicants include higher education institutions (public and private), for-profit organizations, small businesses, nonprofit organizations (501(c)(3) and non-501(c)(3)), tribal governments (federally and non-federally recognized), state and local governments, housing authorities, and special district governments. The program also accepts applications from Alaska Native and Native Hawaiian Serving Institutions, HBCUs, Hispanic-serving Institutions, AANAPISIs, TCCUs, faith-based and community-based organizations, eligible federal agencies, regional organizations, non-domestic entities, and U.S. territories.
Awards are made as cooperative agreements. The funding instrument is a cooperative agreement under CFDA 93.279 (Drug Use and Addiction Research Programs). Support is recommended for a project period not exceeding five years.
NIDA encourages applications employing genomics, multi-omics, and data-based approaches that integrate multi-level omics data, delineate gene networks, and uncover function of known or newly discovered variants. Studies may examine single nucleotide variants, indels, structural variants, and mobile DNA. The program values circuit-level genomics analysis and neuroscience applications to genomics studies. Applications should uncover novel mechanisms contributing to various stages across the substance use disorder trajectory and inform identification of therapeutic targets and strategies.
Scientific and technical merit, research feasibility, potential contribution to addressing the national drug abuse problem, and relevance to NIDA priorities guide funding decisions. Applicant qualifications, budget appropriateness, facilities adequacy, and human or animal subject protections are evaluated. Review typically requires 240 to 270 days from submission.
Synopsis
The purpose of the NIDA Animal Genetics Program is to identify genetic, genomic, and molecular (epi)genetic variants that underlie: 1. Phenotypes associated with addictive behaviors and/or vulnerability to distinct stages along the substance use disorders (SUD) trajectory (e.g. initial/acute use, escalation of use, acquisition of tolerance, dependence, uncontrolled use, abstinence and relapse or recovery); 2. Behaviors associated with SUD (e.g. impulsivity, novelty seeking, delayed discounting, and other genetically-associated phenotypes); and 3. Comorbidities that demonstrate genetic correlations with phenotypes and behaviors linked with SUD (e.g. anxiety, stress, poor maternal care, social defeat, and other paradigms). Applications may examine any type of genomic variant, including single nucleotide variants (SNVs), indels, large and small structural variants, and all types of mobile DNA. NIDA encourages applications that take genomics, multi-omics, and/or data-based approaches that integrate multi-level omics data, delineate gene networks, and/or uncover the function of known or newly discovered genetic or epigenetic variants. Other areas of interest include genomics analysis at the circuit level and the application of neuroscience to genomics studies. NIDA expects these studies to uncover novel mechanisms that contribute to various stages across the SUD trajectory and inform future studies about potential targets and therapeutic strategies for addiction.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Files
| File | Type | Posted |
|---|---|---|
| PAR-24-269-Full-Announcement.html | HTML file | |
| PKG00288358.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity